Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Intradermal vs Intramuscular Influenza Vaccine in Adults
NCT00703651Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2003
- Primary completion
- May 2006
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of inactivated, split-virion influenza vaccine in influenza (3 arms), sponsored by Sanofi. Primary endpoint: Immunogenicity of Inactivated, Split-Virion Influenza Vaccine at 21 days. Started Sep 2003; status: completed.
02
Drugs
inactivated, split-virion influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00703651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703651.